Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Novartis AG NVS

Healthcare  —  Drug Manufacturers General
145.46 2.75 1.93% as of 25 Sep
Market cap
$264.3B
P/E
21.8×
Dividend Champion (5y) Cash Flow Champion (3y) Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Novartis AG (NVS) Business Profile

Updated before January 2025

Company Overview

Novartis AG, headquartered in Basel, Switzerland, is one of the world’s leading pharmaceutical companies. The company was formed in 1996 through the merger of Ciba-Geigy and Sandoz, two Swiss companies with rich histories in the pharmaceutical and chemical industries. Novartis operates globally, with a presence in over 140 countries and a workforce of approximately 100,000 employees. The company is led by CEO Vas Narasimhan, who has been at the helm since 2018, driving innovation and digital transformation within the organization. Novartis is listed on the New York Stock Exchange (NYSE) under the ticker symbol NVS.

Core Business Segments

Novartis operates through two primary business segments: Innovative Medicines and Sandoz (Generics and Biosimilars).

Innovative Medicines

This segment focuses on patented prescription medicines and is further divided into two business units:

  • Pharmaceuticals: This unit develops and markets medicines in areas such as cardiology, oncology, immunology, dermatology, respiratory, neuroscience, and ophthalmology. Key products include:

    • Cosentyx: A treatment for autoimmune diseases like psoriasis and ankylosing spondylitis.
    • Entresto: A heart failure medication.
    • Kisqali: A breast cancer therapy.
    • Zolgensma: A gene therapy for spinal muscular atrophy.

  • Oncology: This unit focuses on cancer treatments, offering a range of therapies for various types of cancers. Key products include:

    • Kymriah: A CAR-T cell therapy for certain blood cancers.
    • Tafinlar + Mekinist: A combination therapy for melanoma and other cancers.

Sandoz (Generics and Biosimilars)

Sandoz is a global leader in generic pharmaceuticals and biosimilars. It provides affordable, high-quality medicines in areas such as anti-infectives, dermatology, and oncology. Key products include biosimilars for blockbuster biologics like Humira and Enbrel, as well as a wide range of generic drugs.

Business Model

Novartis’s business model revolves around innovation, research and development (R&D), and a strong focus on patient outcomes. The company invests heavily in R&D, allocating approximately 20% of its annual revenue to develop new therapies and improve existing ones. Novartis generates revenue through the sale of its patented medicines, generics, and biosimilars. The company also collaborates with academic institutions, biotech firms, and other pharmaceutical companies to co-develop and commercialize new treatments.

Novartis integrates its products and services by leveraging digital technologies and data analytics to enhance drug discovery, clinical trials, and patient care. The company’s digital transformation initiatives, such as the use of artificial intelligence (AI) and machine learning, aim to accelerate innovation and improve operational efficiency.

Strategic Direction

Novartis is focused on becoming a leading medicines company powered by advanced therapy platforms and data science. Key strategic priorities include:

  • Pipeline Expansion: The company is committed to advancing its pipeline of innovative medicines, with a focus on areas such as gene therapy, cell therapy, and radioligand therapy.
  • Sustainability Goals: Novartis aims to achieve carbon neutrality across its operations by 2025 and its entire value chain by 2030. The company is also committed to improving global health by expanding access to medicines in underserved regions.
  • Digital Transformation: Novartis continues to invest in digital technologies to enhance drug discovery, clinical trials, and patient engagement.
  • Portfolio Optimization: The company is streamlining its portfolio by divesting non-core assets and focusing on high-growth areas such as oncology, neuroscience, and cardiovascular diseases.

Competitive Landscape

Novartis operates in a highly competitive pharmaceutical industry. Key competitors include:

  • Pfizer: A global pharmaceutical giant with a strong presence in oncology, vaccines, and rare diseases.
  • Roche: A Swiss pharmaceutical company specializing in oncology, immunology, and diagnostics.
  • Merck & Co.: Known for its innovative cancer therapies and vaccines.
  • Johnson & Johnson: A diversified healthcare company with a strong pharmaceutical division.
  • Amgen: A leader in biotechnology, focusing on oncology, cardiovascular, and inflammatory diseases.

In the generics and biosimilars space, Sandoz competes with companies like Teva Pharmaceuticals, Mylan (now part of Viatris), and Biocon.

Risk Factors

Novartis faces several risks that could impact its business operations and financial performance:

  • Regulatory Risks: The pharmaceutical industry is heavily regulated, and changes in regulations or delays in product approvals could affect Novartis’s ability to bring new products to market.
  • Market Dependence: The company relies on a few blockbuster drugs for a significant portion of its revenue. Any decline in sales of these products due to competition or patent expirations could impact financial performance.
  • Supply Chain Disruptions: Global supply chain challenges, including raw material shortages and transportation issues, could affect the company’s ability to manufacture and distribute its products.
  • Litigation Risks: Novartis is subject to lawsuits and legal claims, including patent disputes and allegations of unethical marketing practices.
  • Currency Fluctuations: As a global company, Novartis is exposed to currency exchange rate fluctuations, which can impact its financial results.

Recent Developments

  • Spin-off of Sandoz: In 2023, Novartis announced the spin-off of its generics and biosimilars division, Sandoz, into a standalone company. This move allows Novartis to focus on its core innovative medicines business.
  • New Product Approvals: Novartis received regulatory approvals for several new therapies, including Pluvicto (a radioligand therapy for prostate cancer) and Scemblix (a treatment for chronic myeloid leukemia).
  • Digital Initiatives: The company launched several digital health initiatives, including AI-powered tools for drug discovery and patient monitoring.
  • COVID-19 Response: Novartis played a significant role in the global response to the COVID-19 pandemic by supporting vaccine production and donating medicines to underserved communities.

Investment Considerations

Strengths

  • Strong pipeline of innovative medicines.
  • Leadership position in oncology, neuroscience, and cardiovascular diseases.
  • Commitment to sustainability and global health.
  • Robust financial performance and dividend payouts.
  • Focus on digital transformation and operational efficiency.

Risks

  • Dependence on a few blockbuster drugs.
  • Exposure to regulatory and litigation risks.
  • Competitive pressures in the pharmaceutical and generics markets.
  • Potential impact of global economic and geopolitical uncertainties.

Conclusion

Novartis AG is a global leader in the pharmaceutical industry, known for its innovative medicines and commitment to improving patient outcomes. With a strong pipeline, strategic focus on high-growth areas, and investments in digital transformation, the company is well-positioned for future growth. However, it faces challenges such as regulatory risks, market dependence, and competitive pressures. Overall, Novartis remains a compelling investment opportunity for those seeking exposure to the healthcare sector, backed by a strong track record of innovation and sustainability initiatives.